Raising Money to Support School Nurses and School Nursing Research: NASN's Endowment Fund.

Have you ever wondered how the National Association of School Nurses (NASN) supports school nursing research and clinical practice degree advancement or how they provide opportunities to strengthen advocacy skills? NASN does this work through an endowment fund which provides annual scholarships and grants to members to support their various professional endeavors.

Prospective Evaluation of Repeatability and Robustness of Radiomic Descriptors in Healthy Brain Tissue Regions In Vivo Across Systematic Variations in T2-Weighted Magnetic Resonance Imaging Acquisition Parameters.

BACKGROUND: Radiomic descriptors from magnetic resonance imaging (MRI) are promising for disease diagnosis and characterization but may be sensitive to differences in imaging parameters. OBJECTIVE: To evaluate the repeatability and robustness of radiomic descriptors within healthy brain tissue regions on prospectively acquired MRI scans; in a test-retest setting, under controlled systematic variations of MRI acquisition parameters, and after postprocessing. STUDY TYPE: Prospective. SUBJECTS: Fifteen healthy participants. FIELD STRENGTH/SEQUENCE: A 3.0 T, axial T2 -weighted 2D turbo spin-echo pulse sequence, 181 scans acquired (2 test/retest reference scans and 12 with systematic variations in contrast weighting, resolution, and acceleration per participant; removing scans with artifacts). ASSESSMENT: One hundred and forty-six radiomic descriptors were extracted from a contiguous 2D region of white matter in each scan, before and after postprocessing. STATISTICAL TESTS: Repeatability was assessed in a test/retest setting and between manual and automated annotations for the reference scan. Robustness was evaluated between the reference scan and each group of variant scans (contrast weighting, resolution, and acceleration). Both repeatability and robustness were quantified as the proportion of radiomic descriptors that fell into distinct ranges of the concordance correlation coefficient (CCC): excellent (CCC > 0.85), good (0.7 ≤ CCC ≤ 0.85), moderate (0.5 ≤ CCC < 0.7), and poor (CCC < 0.5); for unprocessed and postprocessed scans separately. RESULTS: Good to excellent repeatability was observed for 52% of radiomic descriptors between test/retest scans and 48% of descriptors between automated vs. manual annotations, respectively. Contrast weighting (TR/TE) changes were associated with the largest proportion of highly robust radiomic descriptors (21%, after processing). Image resolution changes resulted in the largest proportion of poorly robust radiomic descriptors (97%, before postprocessing). Postprocessing of images with only resolution/acceleration differences resulted in 73% of radiomic descriptors showing poor robustness. DATA CONCLUSIONS: Many radiomic descriptors appear to be nonrobust across variations in MR contrast weighting, resolution, and acceleration, as well in test-retest settings, depending on feature formulation and postprocessing. EVIDENCE LEVEL: 2 TECHNICAL EFFICACY: Stage 2.

Assessment of extended urine protein monitoring frequency in patients receiving bevacizumab.

PURPOSE: Proteinuria monitoring is required for patients receiving bevacizumab. Nonetheless, the frequency of monitoring is not specified in the package insert. A 2014 quality improvement study performed at Yale New Haven Health System (YNHHS) found that proteinuria occurred in 15% (all grade) of the 162 patients evaluated. These results led to decreasing the frequency of proteinuria monitoring from every treatment to every other treatment. The objective of this study is to assess the safety of the extended interval for urine protein (UP) monitoring. METHODS: Patients receiving at least four bevacizumab treatments at YNHHS from January to June 2017 were randomly selected and retrospectively reviewed. The following data were collected: baseline patient characteristics, comorbidities, medication history, and proteinuria monitoring. The grade, prevalence and management of proteinuria were evaluated. The minimum necessary sample size was determined to be 384 treatments to achieve a 95% confidence interval. RESULTS: Fifty-five patients and 388 bevacizumab treatments were evaluated. Urine protein was assessed in 52.5% of treatments. The incidence of proteinuria among patients was 7.2% (grade 2) and 0% (grade 3). Cumulative dose and the number of total bevacizumab doses did not affect the timing for onset or severity of proteinuria. Two patients with UP ≥ 2+ were further monitored using a 24-h urine collection test with negative results. No treatments were held due to proteinuria. CONCLUSION: Monitoring proteinuria every other treatment does not increase the frequency of adverse events. Urine protein is now monitored prior to every third bevacizumab treatment, reducing unnecessary labs and chair time.